Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Xandra Breakefield

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Gene Therapy

Living Beings

Disorders

Devices

Gene Transfer Techniques

Concepts & Ideas

Anatomy

Physiology

Mutation

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Saydam Okay; Shen Yiping; Würdinger Thomas; Senol Ozlem; Boke Elvan; James Marianne F; Tannous Bakhos A; Stemmer-Rachamimov Anat O; Yi Ming; Stephens Robert M; Fraefel Cornel; Gusella James F; Krichevsky Anna M; Breakefield Xandra O
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.
Tannous Bakhos A; Christensen Adam P; Pike Lisa; Wurdinger Thomas; Perry Katherine F; Saydam Okay; Jacobs Andreas H; García-Añoveros Jaime; Weissleder Ralph; Sena-Esteves Miguel; Corey David P; Breakefield Xandra O
Mutant sodium channel for tumor therapy.
Skog Johan; Würdinger Tom; van Rijn Sjoerd; Meijer Dimphna H; Gainche Laura; Sena-Esteves Miguel; Curry William T; Carter Bob S; Krichevsky Anna M; Breakefield Xandra O
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Xandra Breakefield (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Saydam Okay; Shen Yiping; Würdinger Thomas; Senol Ozlem; Boke Elvan; James Marianne F; Tannous Bakhos A; Stemmer-Rachamimov Anat O; Yi Ming; Stephens Robert M; Fraefel Cornel; Gusella James F; Krichevsky Anna M; Breakefield Xandra O
Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway.
Molecular and cellular biology 2009;29(21):5923-40.
2009: Tannous Bakhos A; Christensen Adam P; Pike Lisa; Wurdinger Thomas; Perry Katherine F; Saydam Okay; Jacobs Andreas H; García-Añoveros Jaime; Weissleder Ralph; Sena-Esteves Miguel; Corey David P; Breakefield Xandra O
Mutant sodium channel for tumor therapy.
Molecular therapy : the journal of the American Society of Gene Therapy 2009;17(5):810-9.
2008: Skog Johan; Würdinger Tom; van Rijn Sjoerd; Meijer Dimphna H; Gainche Laura; Sena-Esteves Miguel; Curry William T; Carter Bob S; Krichevsky Anna M; Breakefield Xandra O
Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.
Nature cell biology 2008;10(12):1470-6.
2008: Würdinger Thomas; Tannous Bakhos A; Saydam Okay; Skog Johan; Grau Stephan; Soutschek Jürgen; Weissleder Ralph; Breakefield Xandra O; Krichevsky Anna M
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells.
Cancer cell 2008;14(5):382-93.
2008: Nery Flávia C; Zeng Juan; Niland Brian P; Hewett Jeffrey; Farley Jonathan; Irimia Daniel; Li Yuqing; Wiche Gerhard; Sonnenberg Arnoud; Breakefield Xandra O
TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton.
Journal of cell science 2008;121(Pt 20):3476-86.
2008: Maguire Casey A; Meijer Dimphna H; LeRoy Stanley G; Tierney Laryssa A; Broekman Marike L D; Costa Fabricio F; Breakefield Xandra O; Stemmer-Rachamimov Anat; Sena-Esteves Miguel
Preventing growth of brain tumors by creating a zone of resistance.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(10):1695-702.
2008: de Oliveira Anna Paula; Glauser Daniel L; Laimbacher Andrea S; Strasser Regina; Schraner Elisabeth M; Wild Peter; Ziegler Urs; Breakefield Xandra O; Ackermann Mathias; Fraefel Cornel
Live visualization of herpes simplex virus type 1 compartment dynamics.
Journal of virology 2008;82(10):4974-90.
2008: Hewett Jeffrey W; Nery Flávia C; Niland Brian; Ge Pei; Tan Pamela; Hadwiger Philipp; Tannous Bakhos A; Sah Dinah W Y; Breakefield Xandra O
siRNA knock-down of mutant torsinA restores processing through secretory pathway in DYT1 dystonia cells.
Human molecular genetics 2008;17(10):1436-45.
2008: Breakefield Xandra O; Blood Anne J; Li Yuqing; Hallett Mark; Hanson Phyllis I; Standaert David G
The pathophysiological basis of dystonias.
Nature reviews. Neuroscience 2008;9(3):222-34.
2008: Wurdinger Thomas; Badr Christian; Pike Lisa; de Kleine Ruben; Weissleder Ralph; Breakefield Xandra O; Tannous Bakhos A
A secreted luciferase for ex vivo monitoring of in vivo processes.
Nature methods 2008;5(2):171-3.
2008: Cortés Maria L; Oehmig Angelika; Saydam Okay; Sanford Jocelyn D; Perry Katherine F; Fraefel Cornel; Breakefield Xandra O
Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(1):81-8.
2007: Balcioglu Aygul; Kim Mee-Ohk; Sharma Nutan; Cha Jang-Ho; Breakefield Xandra O; Standaert David G
Dopamine release is impaired in a mouse model of DYT1 dystonia.
Journal of neurochemistry 2007;102(3):783-8.
2007: Oehmig A; Cortés M L; Perry K F; Sena-Esteves M; Fraefel Cornel; Breakefield X O
Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector.
Gene therapy 2007;14(14):1078-91.
2007: Prabhakar S; Messerli S M; Stemmer-Rachamimov A O; Liu T-C; Rabkin S; Martuza R; Breakefield X O
Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.
Cancer gene therapy 2007;14(5):460-7.
2007: Hewett Jeffrey W; Tannous Bakhos; Niland Brian P; Nery Flavia C; Zeng Juan; Li Yuqing; Breakefield Xandra O
Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(17):7271-6.
2007: Badr Christian E; Hewett Jeffrey W; Breakefield Xandra O; Tannous Bakhos A
A highly sensitive assay for monitoring the secretory pathway and ER stress.
PloS one 2007;2(6):e571.
2006: Bahn E; Siegert S; Pfander T; Kramer M L; Schulz-Schaeffer W J; Hewett J W; Breakefield X O; Hedreen J C; Rostásy K M
TorsinB expression in the developing human brain.
Brain research 2006;1116(1):112-9.
2006: Cortés M L; Oehmig A; Perry K F; Sanford J D; Breakefield X O
Expression of human ATM cDNA in Atm-deficient mouse brain mediated by HSV-1 amplicon vector.
Neuroscience 2006;141(3):1247-56.
2006: Shah Khalid; Breakefield Xandra O
HSV amplicon vectors for cancer therapy.
Current gene therapy 2006;6(3):361-70.
2006: Tannous Bakhos A; Grimm Jan; Perry Katherine F; Chen John W; Weissleder Ralph; Breakefield Xandra O
Metabolic biotinylation of cell surface receptors for in vivo imaging.
Nature methods 2006;3(5):391-6.
2006: Kock Norman; Naismith Teresa V; Boston Heather E; Ozelius Laurie J; Corey David P; Breakefield Xandra O; Hanson Phyllis I
Effects of genetic variations in the dystonia protein torsinA: identification of polymorphism at residue 216 as protein modifier.
Human molecular genetics 2006;15(8):1355-64.
2006: Hewett Jeffrey W; Zeng Juan; Niland Brian P; Bragg D Cristopher; Breakefield Xandra O
Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics.
Neurobiology of disease 2006;22(1):98-111.
2006: McKee Trevor D; Grandi Paola; Mok Wilson; Alexandrakis George; Insin Numpon; Zimmer John P; Bawendi Moungi G; Boucher Yves; Breakefield Xandra O; Jain Rakesh K
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector.
Cancer research 2006;66(5):2509-13.
2006: Kock Norman; Allchorne Andrew J; Sena-Esteves Miguel; Woolf Clifford J; Breakefield Xandra O
RNAi blocks DYT1 mutant torsinA inclusions in neurons.
Neuroscience letters 2006;395(3):201-5.
2006: Vasudevan Anju; Breakefield Xandra O; Bhide Pradeep G
Developmental patterns of torsinA and torsinB expression.
Brain research 2006;1073-1074():139-45.
2006: Messerli Shanta M; Prabhakar Shilpa; Tang Yi; Mahmood Umar; Giovannini Marco; Weissleder Ralph; Bronson Rodrick; Martuza Robert; Rabkin Samuel; Breakefield Xandra O
Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2.
Human gene therapy 2006;17(1):20-30.
2005: Brown Alice B; Mahmood Umar; Cortes Maria L; Tang Yi; Dai George; Stemmer-Rachamimov Anat; Prabhakar Shilpa; Leishear Kimberlee; Onda Hiroaki; Kwiatkowski David; Weissleder Ralph; Breakefield Xandra
Magnetic resonance imaging and characterization of spontaneous lesions in a transgenic mouse model of tuberous sclerosis as a model for endothelial cell-based transgene delivery.
Human gene therapy 2005;16(12):1367-76.
2005: Siegert S; Bahn E; Kramer M L; Schulz-Schaeffer W J; Hewett J W; Breakefield X O; Hedreen J C; Rostasy K M
TorsinA expression is detectable in human infants as young as 4 weeks old.
Brain research. Developmental brain research 2005;157(1):19-26.
2005: Sharma Nutan; Baxter Mark G; Petravicz Jeremy; Bragg D Cristopher; Schienda Alonna; Standaert David G; Breakefield Xandra O
Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2005;25(22):5351-5.
2005: Shah Khalid; Tung Ching-Hsuan; Breakefield Xandra O; Weissleder Ralph
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis.
Molecular therapy : the journal of the American Society of Gene Therapy 2005;11(6):926-31.
2005: Tannous Bakhos A; Kim Dong-Eog; Fernandez Juliet L; Weissleder Ralph; Breakefield Xandra O
Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo.
Molecular therapy : the journal of the American Society of Gene Therapy 2005;11(3):435-43.
2005: Shah Khalid; Bureau Emilie; Kim Dong-Eog; Yang Katherine; Tang Yi; Weissleder Ralph; Breakefield Xandra O
Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression.
Annals of neurology 2005;57(1):34-41.
2004: Oehmig Angelika; Fraefel Cornel; Breakefield Xandra O; Ackermann Mathias
Herpes simplex virus type 1 amplicons and their hybrid virus partners, EBV, AAV, and retrovirus.
Current gene therapy 2004;4(4):385-408.
2004: Bragg D Cristopher; Kaufman Caroline A; Kock Norman; Breakefield Xandra O
Inhibition of N-linked glycosylation prevents inclusion formation by the dystonia-related mutant form of torsinA.
Molecular and cellular neurosciences 2004;27(4):417-26.
2004: Oehmig Angelika; Fraefel Cornel; Breakefield Xandra O
Update on herpesvirus amplicon vectors.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;10(4):630-43.
2004: Shah K; Jacobs A; Breakefield X O; Weissleder R
Molecular imaging of gene therapy for cancer.
Gene therapy 2004;11(15):1175-87.
2004: Kamm Christoph; Leung Joanne; Joseph Soni; Dobyns William B; Brashear Alison; Breakefield Xandra O; Ozelius Laurie J
Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene.
Movement disorders : official journal of the Movement Disorder Society 2004;19(7):845-7.
2004: Bagley Jessamyn; Cortes Maria L; Breakefield Xandra O; Iacomini John
Bone marrow transplantation restores immune system function and prevents lymphoma in Atm-deficient mice.
Blood 2004;104(2):572-8.
2004: Hewett Jeffrey W; Kamm Christoph; Boston Heather; Beauchamp Roberta; Naismith Teri; Ozelius Laurie; Hanson Phyllis I; Breakefield Xandra O; Ramesh Vijaya
TorsinB--perinuclear location and association with torsinA.
Journal of neurochemistry 2004;89(5):1186-94.
2004: Grandi Paola; Spear Matthew; Breakefield Xandra O; Wang Samuel
Targeting HSV amplicon vectors.
Methods (San Diego, Calif.) 2004;33(2):179-86.
2004: Naismith Teresa V; Heuser John E; Breakefield Xandra O; Hanson Phyllis I
TorsinA in the nuclear envelope.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(20):7612-7.
2004: Shah Khalid; Tung Ching-Hsuan; Yang Katherine; Weissleder Ralph; Breakefield Xandra O
Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy.
Cancer research 2004;64(9):3236-42.
2004: Lafreniere Ronald G; MacDonald Marcia L E; Dube Marie-Pierre; MacFarlane Julie; O'Driscoll Mary; Brais Bernard; Meilleur Sebastien; Brinkman Ryan R; Dadivas Owen; Pape Terry; Platon Christele; Radomski Chris; Risler Jenni; Thompson Jay; Guerra-Escobio Ana-Maria; Davar Gudarz; Breakefield Xandra O; Pimstone Simon N; Green Roger; Pryse-Phillips William; Goldberg Y Paul; Younghusband H Banfield; Hayden Michael R; Sherrington Robin; Rouleau Guy A; Samuels Mark E;
Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates.
American journal of human genetics 2004;74(5):1064-73.
2004: Kamm Christoph; Boston Heather; Hewett Jeffrey; Wilbur Jeremy; Corey David P; Hanson Phyllis I; Ramesh Vijaya; Breakefield Xandra O
The early onset dystonia protein torsinA interacts with kinesin light chain 1.
The Journal of biological chemistry 2004;279(19):19882-92.
2004: Shah Khalid; Hsich Gary; Breakefield Xandra O
Neural precursor cells and their role in neuro-oncology.
Developmental neuroscience 2004;26(2-4):118-30.
2004: Messerli Shanta M; Prabhakar Shilpa; Tang Yi; Shah Khalid; Cortes Maria L; Murthy Vidya; Weissleder Ralph; Breakefield Xandra O; Tung Ching-Hsuan
A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe.
Neoplasia (New York, N.Y.) 2004;6(2):95-105.
2004: Grandi Paola; Wang Samuel; Schuback Deborah; Krasnykh Victor; Spear Matthew; Curiel David T; Manservigi Roberto; Breakefield Xandra O
HSV-1 virions engineered for specific binding to cell surface receptors.
Molecular therapy : the journal of the American Society of Gene Therapy 2004;9(3):419-27.
2004: Kabakci K; Hedrich K; Leung J C; Mitterer M; Vieregge P; Lencer R; Hagenah J; Garrels J; Witt K; Klostermann F; Svetel M; Friedman J; Kostic V; Bressman S B; Breakefield X O; Ozelius L J; Pramstaller P P; Klein C
Mutations in DYT1: extension of the phenotypic and mutational spectrum.
Neurology 2004;62(3):395-400.
2004: Shah Khalid; Tung Ching-Hsuan; Chang Chung-Hsun; Slootweg Eric; O'Loughlin Terence; Breakefield Xandra O; Weissleder Ralph
In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas.
Cancer research 2004;64(1):273-8.
2004: Bragg D C; Camp S M; Kaufman C A; Wilbur J D; Boston H; Schuback D E; Hanson P I; Sena-Esteves M; Breakefield X O
Perinuclear biogenesis of mutant torsin-A inclusions in cultured cells infected with tetracycline-regulated herpes simplex virus type 1 amplicon vectors.
Neuroscience 2004;125(3):651-61.
2004: Bragg D Cristopher; Slater Damien J; Breakefield Xandra O
TorsinA and early-onset torsion dystonia.
Advances in neurology 2004;94():87-93.
2004: Augood Sarah J; Hollingsworth Z; Albers David S; Yang Lichuan; Leung Joanne; Breakefield Xandra O; Standaert David G
Dopamine transmission in DYT1 dystonia.
Advances in neurology 2004;94():53-60.
2003: Brown Alice B; Yang Wendy; Schmidt Nils O; Carroll Rona; Leishear Kim K; Rainov Nikolai G; Black Peter M; Breakefield Xandra O; Aboody Karen S
Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin.
Human gene therapy 2003;14(18):1777-85.
2003: Yoshimura Shinichi; Teramoto Tetsuyuki; Whalen Michael J; Irizarry Michael C; Takagi Yasushi; Qiu Jianhua; Harada Jun; Waeber Christian; Breakefield Xandra O; Moskowitz Michael A
FGF-2 regulates neurogenesis and degeneration in the dentate gyrus after traumatic brain injury in mice.
The Journal of clinical investigation 2003;112(8):1202-10.
2003: Shah Khalid; Tang Yi; Breakefield Xandra; Weissleder Ralph
Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo.
Oncogene 2003;22(44):6865-72.
2003: Augood Sarah J; Keller-McGandy Christine E; Siriani Ana; Hewett Jeffrey; Ramesh Vijaya; Sapp Ellen; DiFiglia Marion; Breakefield Xandra O; Standaert David G
Distribution and ultrastructural localization of torsinA immunoreactivity in the human brain.
Brain research 2003;986(1-2):12-21.
2003: Tang Yi; Shah Khalid; Messerli Shanta M; Snyder Evan; Breakefield Xandra; Weissleder Ralph
In vivo tracking of neural progenitor cell migration to glioblastomas.
Human gene therapy 2003;14(13):1247-54.
2003: Cortés M L; Bakkenist C J; Di Maria M V; Kastan M B; Breakefield X O
HSV-1 amplicon vector-mediated expression of ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype.
Gene therapy 2003;10(16):1321-7.
2003: Simon David K; Friedman Jennifer; Breakefield Xandra O; Jankovic Joseph; Brin Mitchell F; Provias John; Bressman Susan B; Charness Michael E; Tarsy Daniel; Johns Donald R; Tarnopolsky Mark A
A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia.
Neurogenetics 2003;4(4):199-205.
2003: Wang Samuel; Petravicz Jeremy; Breakefield Xandra O
Single HSV-amplicon vector mediates drug-induced gene expression via dimerizer system.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;7(6):790-800.
2003: Hampl Jürgen A; Camp Sara M; Mydlarz Wojciech K; Hampl Monika; Ichikawa Tomotsuga; Chiocca E Antonio; Louis David N; Sena-Esteves Miguel; Breakefield Xandra O
Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors.
Human gene therapy 2003;14(7):611-26.
2003: Davidson Beverly L; Breakefield Xandra O
Viral vectors for gene delivery to the nervous system.
Nature reviews. Neuroscience 2003;4(5):353-64.
2003: Hewett Jeffrey; Ziefer Philipp; Bergeron Daniele; Naismith Teri; Boston Heather; Slater Damien; Wilbur Jeremy; Schuback Deborah; Kamm Christoph; Smith Nicole; Camp Sara; Ozelius Laurie J; Ramesh Vijaya; Hanson Phyllis I; Breakefield Xandra O
TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress.
Journal of neuroscience research 2003;72(2):158-68.
2003: Rostasy Kevin; Augood Sarah J; Hewett Jeffrey W; Leung Joanne Chung-on; Sasaki Hikaru; Ozelius Laurie J; Ramesh Vijaya; Standaert David G; Breakefield Xandra O; Hedreen John C
TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion.
Neurobiology of disease 2003;12(1):11-24.
2003: Spear Matthew A; Schuback Deborah; Miyata Kenichi; Grandi Paola; Sun Fang; Yoo Linda; Nguyen Anh; Brandt Curtis R; Breakefield Xandra O
HSV-1 amplicon peptide display vector.
Journal of virological methods 2003;107(1):71-9.
2003: Saeki Yoshinaga; Breakefield Xandra O; Chiocca E Antonio
Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA.
Methods in molecular medicine 2003;76():51-60.
2002: Lam Paula; Hui Kam M; Wang Yaming; Allen Paul D; Louis David N; Yuan C J; Breakefield Xandra O
Dynamics of transgene expression in human glioblastoma cells mediated by herpes simplex virus/adeno-associated virus amplicon vectors.
Human gene therapy 2002;13(18):2147-59.
2002: Sandler Vladislav M; Wang Samuel; Angelo Kamilla; Lo Helen G; Breakefield Xandra O; Clapham David E
Modified herpes simplex virus delivery of enhanced GFP into the central nervous system.
Journal of neuroscience methods 2002;121(2):211-9.
2002: McLean Pamela J; Kawamata Hibiki; Shariff Saadat; Hewett Jeffrey; Sharma Nutan; Ueda Kenji; Breakefield Xandra O; Hyman Bradley T
TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation.
Journal of neurochemistry 2002;83(4):846-54.
2002: Messerli S M; Tang Y; Giovannini M; Bronson R; Weissleder R; Breakefield X O
Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2.
Neoplasia (New York, N.Y.) 2002;4(6):501-9.
2002: Klein Christine; Liu Liu; Doheny Dana; Kock Norman; Müller Birgitt; de Carvalho Aguiar Patricia; Leung Joanne; de Leon Deborah; Bressman Susan B; Silverman Jeremy; Smith Christopher; Danisi Fabio; Morrison Chris; Walker Ruth H; Velickovic Miodrag; Schwinger Eberhard; Kramer Patricia L; Breakefield Xandra O; Brin Mitchell F; Ozelius Laurie J
Epsilon-sarcoglycan mutations found in combination with other dystonia gene mutations.
Annals of neurology 2002;52(5):675-9.
2002: Doheny D; Danisi F; Smith C; Morrison C; Velickovic M; De Leon D; Bressman S B; Leung J; Ozelius L; Klein C; Breakefield X O; Brin M F; Silverman J M
Clinical findings of a myoclonus-dystonia family with two distinct mutations.
Neurology 2002;59(8):1244-6.
2002: Augood Sarah J; Hollingsworth Z; Albers D S; Yang L; Leung J-C; Muller B; Klein C; Breakefield X O; Standaert D G
Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study.
Neurology 2002;59(3):445-8.
2002: Pal Pramod K; Leung Joanne; Hedrich Katya; Samii Ali; Lieberman Abraham; Nausieda Paul A; Calne Donald B; Breakefield Xandra O; Klein Christine; Stoessl A Jon
[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism.
Movement disorders : official journal of the Movement Disorder Society 2002;17(4):789-94.
2002: Sena-Esteves Miguel; Hampl Jürgen A; Camp Sara M; Breakefield Xandra O
Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors.
The journal of gene medicine 2002;4(3):229-39.
2002: Kann Martin; Jacobs Helfried; Mohrmann Kathrin; Schumacher Kirsten; Hedrich Katja; Garrels Jennifer; Wiegers Karin; Schwinger Eberhard; Pramstaller Peter P; Breakefield Xandra O; Ozelius Laurie J; Vieregge Peter; Klein Christine
Role of parkin mutations in 111 community-based patients with early-onset parkinsonism.
Annals of neurology 2002;51(5):621-5.
2002: Ziefer Philipp; Leung Joanne; Razzano Tara; Shalish Christo; LeDoux Mark S; Lorden Joan F; Ozelius Laurie; Breakefield Xandra O; Standaert David G; Augood Sarah J
Molecular cloning and expression of rat torsinA in the normal and genetically dystonic (dt) rat.
Brain research. Molecular brain research 2002;101(1-2):132-5.
2002: Pramstaller Peter P; Kis Bernhard; Eskelson Cordula; Hedrich Katja; Scherer Monika; Schwinger Eberhard; Breakefield Xandra O; Kramer Patricia L; Ozelius Laurie J; Klein Christine
Phenotypic variability in a large kindred (Family LA) with deletions in the parkin gene.
Movement disorders : official journal of the Movement Disorder Society 2002;17(2):424-6.
2002: Opal Puneet; Tintner Ron; Jankovic Joseph; Leung Joanne; Breakefield Xandra O; Friedman Jennifer; Ozelius Laurie
Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm.
Movement disorders : official journal of the Movement Disorder Society 2002;17(2):339-45.
2002: Hsich Gary; Sena-Esteves Miguel; Breakefield Xandra O
Critical issues in gene therapy for neurologic disease.
Human gene therapy 2002;13(5):579-604.
2002: Wang Yaming; Mukherjee Santwana; Fraefel Cornel; Breakefield Xandra O; Allen Paul D
Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle.
Human gene therapy 2002;13(2):261-73.
2002: Costantini Lauren C; Fraefel Cornel; Breakefield Xandra O; Isacson Ole
Herpes simplex virus/adeno-associated virus hybrid vectors for gene transfer to neurons. Preparation and use.
Methods in molecular medicine 2002;69():461-79.
2002: Wang Sam; Fraefel Cornel; Breakefield Xandra
HSV-1 amplicon vectors.
Methods in enzymology 2002;346():593-603.
2001: Hedrich K; Kann M; Lanthaler A J; Dalski A; Eskelson C; Landt O; Schwinger E; Vieregge P; Lang A E; Breakefield X O; Ozelius L J; Pramstaller P P; Klein C
The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism.
Human molecular genetics 2001;10(16):1649-56.
2001: Leung J C; Klein C; Friedman J; Vieregge P; Jacobs H; Doheny D; Kamm C; DeLeon D; Pramstaller P P; Penney J B; Eisengart M; Jankovic J; Gasser T; Bressman S B; Corey D P; Kramer P; Brin M F; Ozelius L J; Breakefield X O
Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism.
Neurogenetics 2001;3(3):133-43.
2001: Spear M A; Breakefield X O; Beltzer J; Schuback D; Weissleder R; Pardo F S; Ladner R
Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells.
Cancer gene therapy 2001;8(7):506-11.
2001: Breakefield X O; Kamm C; Hanson P I
TorsinA: movement at many levels.
Neuron 2001;31(1):9-12.
2001: Sharma N; Hewett J; Ozelius L J; Ramesh V; McLean P J; Breakefield X O; Hyman B T
A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study.
The American journal of pathology 2001;159(1):339-44.
2001: Jacobs A; Tjuvajev J G; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson S M; Herrlinger U; Pechan P A; Chiocca E A; Breakefield X O; Blasberg R G
Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Cancer research 2001;61(7):2983-95.
2001: Lam P Y; Breakefield X O
Potential of gene therapy for brain tumors.
Human molecular genetics 2001;10(7):777-87.
2000: Lam P Y; Breakefield X O
Hybrid vector designs to control the delivery, fate and expression of transgenes.
The journal of gene medicine 2000;2(6):395-408.
2000: Friedman J R; Klein C; Leung J; Woodward H; Ozelius L J; Breakefield X O; Charness M E
The GAG deletion of the DYT1 gene is infrequent in musicians with focal dystonia.
Neurology 2000;55(9):1417-8.
2000: Aboody K S; Brown A; Rainov N G; Bower K A; Liu S; Yang W; Small J E; Herrlinger U; Ourednik V; Black P M; Breakefield X O; Snyder E Y
Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(23):12846-51.
2000: Klein C; Schilling K; Saunders-Pullman R J; Garrels J; Breakefield X O; Brin M F; deLeon D; Doheny D; Fahn S; Fink J S; Forsgren L; Friedman J; Frucht S; Harris J; Holmgren G; Kis B; Kurlan R; Kyllerman M; Lang A E; Leung J; Raymond D; Robishaw J D; Sanner G; Schwinger E; Tabamo R E; Tagliati M
A major locus for myoclonus-dystonia maps to chromosome 7q in eight families.
American journal of human genetics 2000;67(5):1314-9.
2000: Herrlinger U; Jacobs A; Quinones A; Woiciechowsky C; Sena-Esteves M; Rainov N G; Fraefel C; Breakefield X O
Helper virus-free herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma.
Human gene therapy 2000;11(10):1429-38.
2000: Klein C; Pramstaller P P; Kis B; Page C C; Kann M; Leung J; Woodward H; Castellan C C; Scherer M; Vieregge P; Breakefield X O; Kramer P L; Ozelius L J
Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype.
Annals of neurology 2000;48(1):65-71.
2000: Klein C; Kann M; Kis B; Pramstaller P P; Breakefield X O; Ozelius L J; Vieregge P
[Genetics of dystonia]
Der Nervenarzt 2000;71(6):431-41.
2000: Aghi M; Hochberg F; Breakefield X O
Prodrug activation enzymes in cancer gene therapy.
The journal of gene medicine 2000;2(3):148-64.
2000: Hewett J; Gonzalez-Agosti C; Slater D; Ziefer P; Li S; Bergeron D; Jacoby D J; Ozelius L J; Ramesh V; Breakefield X O
Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells.
Human molecular genetics 2000;9(9):1403-13.
2000: Bressman S B; Sabatti C; Raymond D; de Leon D; Klein C; Kramer P L; Brin M F; Fahn S; Breakefield X; Ozelius L J; Risch N J
The DYT1 phenotype and guidelines for diagnostic testing.
Neurology 2000;54(9):1746-52.
2000: Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody K S; Jacobs A H; Rainov N G; Snyder E Y; Breakefield X O
Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
Molecular therapy : the journal of the American Society of Gene Therapy 2000;1(4):347-57.
2000: Sena-Esteves M; Camp S M; Alroy J; Breakefield X O; Kaye E M
Correction of acid beta-galactosidase deficiency in GM1 gangliosidosis human fibroblasts by retrovirus vector-mediated gene transfer: higher efficiency of release and cross-correction by the murine enzyme.
Human gene therapy 2000;11(5):715-27.
2000: Klein C; Gurvich N; Sena-Esteves M; Bressman S; Brin M F; Ebersole B J; Fink S; Forsgren L; Friedman J; Grimes D; Holmgren G; Kyllerman M; Lang A E; de Leon D; Leung J; Prioleau C; Raymond D; Sanner G; Saunders-Pullman R; Vieregge P; Wahlström J; Breakefield X O; Kramer P L; Ozelius L J; Sealfon S C
Evaluation of the role of the D2 dopamine receptor in myoclonus dystonia.
Annals of neurology 2000;47(3):369-73.
2000: Costantini L C; Bakowska J C; Breakefield X O; Isacson O
Gene therapy in the CNS.
Gene therapy 2000;7(2):93-109.
1999: Ozelius L J; Page C E; Klein C; Hewett J W; Mineta M; Leung J; Shalish C; Bressman S B; de Leon D; Brin M F; Fahn S; Corey D P; Breakefield X O
The TOR1A (DYT1) gene family and its role in early onset torsion dystonia.
Genomics 1999;62(3):377-84.
1999: Sena-Esteves M; Saeki Y; Camp S M; Chiocca E A; Breakefield X O
Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.
Journal of virology 1999;73(12):10426-39.
1999: Augood S J; Martin D M; Ozelius L J; Breakefield X O; Penney J B; Standaert D G
Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain.
Annals of neurology 1999;46(5):761-9.
1999: Costantini L C; Jacoby D R; Wang S; Fraefel C; Breakefield X O; Isacson O
Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors.
Human gene therapy 1999;10(15):2481-94.
1999: Aghi M; Chou T C; Suling K; Breakefield X O; Chiocca E A
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.
Cancer research 1999;59(16):3861-5.
1999: Kramer P L; Mineta M; Klein C; Schilling K; de Leon D; Farlow M R; Breakefield X O; Bressman S B; Dobyns W B; Ozelius L J; Brashear A
Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13.
Annals of neurology 1999;46(2):176-82.
1999: Klein C; Vieregge P; Hagenah J; Sieberer M; Doyle E; Jacobs H; Gasser T; Breakefield X O; Risch N J; Ozelius L J
Search for the PARK3 founder haplotype in a large cohort of patients with Parkinson's disease from northern Germany.
Annals of human genetics 1999;63(Pt 4):285-91.
1999: Aghi M; Kramm C M; Breakefield X O
Folylpolyglutamyl synthetase gene transfer and glioma antifolate sensitivity in culture and in vivo.
Journal of the National Cancer Institute 1999;91(14):1233-41.
1999: Jacobs A; Dubrovin M; Hewett J; Sena-Esteves M; Tan C W; Slack M; Sadelain M; Breakefield X O; Tjuvajev J G
Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression.
Neoplasia (New York, N.Y.) 1999;1(2):154-61.
1999: Pechan P A; Herrlinger U; Aghi M; Jacobs A; Breakefield X O
Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
The journal of gene medicine 1999;1(3):176-85.
1999: Klein C; Brin M F; Kramer P; Sena-Esteves M; de Leon D; Doheny D; Bressman S; Fahn S; Breakefield X O; Ozelius L J
Association of a missense change in the D2 dopamine receptor with myoclonus dystonia.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(9):5173-6.
1999: Schuback D E; Mulligan E L; Sims K B; Tivol E A; Greenberg B D; Chang S F; Yang S L; Mau Y C; Shen C Y; Ho M S; Yang N H; Butler M G; Fink S; Schwartz C E; Berlin F; Breakefield X O; Murphy D L; Hsu Y P
Screen for MAOA mutations in target human groups.
American journal of medical genetics 1999;88(1):25-8.
1999: Klein C; Page C E; LeWitt P; Gordon M F; de Leon D; Awaad Y; Breakefield X O; Brin M F; Ozelius L J
Genetic analysis of three patients with an 18p- syndrome and dystonia.
Neurology 1999;52(3):649-51.
1999: Barnett F H; Rainov N G; Ikeda K; Schuback D E; Elliott P; Kramm C M; Chase M; Qureshi N H; Harsh G; Chiocca E A; Breakefield X O
Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7.
Cancer gene therapy 1999;6(1):14-20.
1999: Rainov N G; Ikeda K; Qureshi N H; Grover S; Herrlinger U; Pechan P; Chiocca E A; Breakefield X O; Barnett F H
Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms.
Human gene therapy 1999;10(2):311-8.
1999: Klein C; Breakefield X O; Ozelius L J
Genetics of primary dystonia.
Seminars in neurology 1999;19(3):271-80.
1999: Klein C; Friedman J; Bressman S; Vieregge P; Brin M F; Pramstaller P P; De Leon D; Hagenah J; Sieberer M; Fleet C; Kiely R; Xin W; Breakefield X O; Ozelius L J; Sims K B
Genetic testing for early-onset torsion dystonia (DYT1): introduction of a simple screening method, experiences from testing of a large patient cohort, and ethical aspects.
Genetic testing 1999;3(4):323-8.
1999: Rainov N G; Ikeda K; Qureshi N; Grover S; Barnett F H; Herrlinger U; Quinones A; Chiocca E A; Breakefield X O
Intra-arterial virus and nonvirus vector-mediated gene transfer to experimental rat brain tumors.
Frontiers of radiation therapy and oncology 1999;33():227-40.
1998: Saeki Y; Ichikawa T; Saeki A; Chiocca E A; Tobler K; Ackermann M; Breakefield X O; Fraefel C
Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors.
Human gene therapy 1998;9(18):2787-94.
1998: Klein C; Ozelius L J; Hagenah J; Breakefield X O; Risch N J; Vieregge P
Search for a founder mutation in idiopathic focal dystonia from Northern Germany.
American journal of human genetics 1998;63(6):1777-82.
1998: Klein C; Vieregge P; Heide W; Kemper B; Hagedorn-Greiwe M; Hagenah J; Vollmer C; Breakefield X O; Kömpf D; Ozelius L
Exclusion of chromosome regions 6p12 and 15q11, but not chromosome region 7p11, in a German family with autosomal dominant congenital nystagmus.
Genomics 1998;54(1):176-7.
1998: Klein C; Pramstaller P P; Castellan C C; Breakefield X O; Kramer P L; Ozelius L J
Clinical and genetic evaluation of a family with a mixed dystonia phenotype from South Tyrol.
Annals of neurology 1998;44(3):394-8.
1998: Schellingerhout D; Bogdanov A; Marecos E; Spear M; Breakefield X; Weissleder R
Mapping the in vivo distribution of herpes simplex virions.
Human gene therapy 1998;9(11):1543-9.
1998: Klein C; Brin M F; de Leon D; Limborska S A; Ivanova-Smolenskaya I A; Bressman S B; Friedman A; Markova E D; Risch N J; Breakefield X O; Ozelius L J
De novo mutations (GAG deletion) in the DYT1 gene in two non-Jewish patients with early-onset dystonia.
Human molecular genetics 1998;7(7):1133-6.
1998: Herrlinger U; Kramm C M; Aboody-Guterman K S; Silver J S; Ikeda K; Johnston K M; Pechan P A; Barth R F; Finkelstein D; Chiocca E A; Louis D N; Breakefield X O
Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector.
Gene therapy 1998;5(6):809-19.
1998: Rainov N G; Dobberstein K U; Sena-Esteves M; Herrlinger U; Kramm C M; Philpot R M; Hilton J; Chiocca E A; Breakefield X O
New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol.
Human gene therapy 1998;9(9):1261-73.
1998: Rainov N G; Dobberstein K U; Heidecke V; Dorant U; Chase M; Kramm C M; Chiocca E A; Breakefield X O
Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector.
Cancer gene therapy 1998;5(3):158-62.
1998: Bagley J; Aboody-Guterman K; Breakefield X; Iacomini J
Long-term expression of the gene encoding green fluorescent protein in murine hematopoietic cells using retroviral gene transfer.
Transplantation 1998;65(9):1233-40.
1998: Augood S J; Penney J B; Friberg I K; Breakefield X O; Young A B; Ozelius L J; Standaert D G
Expression of the early-onset torsion dystonia gene (DYT1) in human brain.
Annals of neurology 1998;43(5):669-73.
1998: Spear M A; Herrlinger U; Rainov N; Pechan P; Weissleder R; Breakefield X O
Targeting gene therapy vectors to CNS malignancies.
Journal of neurovirology 1998;4(2):133-47.
1998: Aghi M; Kramm C M; Chou T C; Breakefield X O; Chiocca E A
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.
Journal of the National Cancer Institute 1998;90(5):370-80.
1998: Rainov N G; Sena-Esteves M; Fraefel C; Dobberstein K U; Chiocca E A; Breakefield X O
A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma.
Advances in experimental medicine and biology 1998;451():393-403.
1998: Bressman S B; de Leon D; Raymond D; Greene P E; Brin M F; Fahn S; Ozelius L J; Breakefield X O; Kramer P L; Risch N J
The role of the DYT1 gene in secondary dystonia.
Advances in neurology 1998;78():107-15.
1998: Ozelius L J; Hewett J W; Page C E; Bressman S B; Kramer P L; Shalish C; de Leon D; Brin M F; Raymond D; Jacoby D; Penney J; Risch N J; Fahn S; Gusella J F; Breakefield X O
The gene (DYT1) for early-onset torsion dystonia encodes a novel protein related to the Clp protease/heat shock family.
Advances in neurology 1998;78():93-105.
1998: Bressman S B; de Leon D; Raymond D; Ozelius L J; Breakefield X O; Nygaard T G; Almasy L; Risch N J; Kramer P L
Clinical-genetic spectrum of primary dystonia.
Advances in neurology 1998;78():79-91.
1997: Fraefel C; Jacoby D R; Lage C; Hilderbrand H; Chou J Y; Alt F W; Breakefield X O; Majzoub J A
Gene transfer into hepatocytes mediated by helper virus-free HSV/AAV hybrid vectors.
Molecular medicine (Cambridge, Mass.) 1997;3(12):813-25.
1997: Aboody-Guterman K S; Pechan P A; Rainov N G; Sena-Esteves M; Jacobs A; Snyder E Y; Wild P; Schraner E; Tobler K; Breakefield X O; Fraefel C
Green fluorescent protein as a reporter for retrovirus and helper virus-free HSV-1 amplicon vector-mediated gene transfer into neural cells in culture and in vivo.
Neuroreport 1997;8(17):3801-8.
1997: Kramm C M; Chase M; Herrlinger U; Jacobs A; Pechan P A; Rainov N G; Sena-Esteves M; Aghi M; Barnett F H; Chiocca E A; Breakefield X O
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
Human gene therapy 1997;8(17):2057-68.
1997: Herrlinger U; Kramm C M; Johnston K M; Louis D N; Finkelstein D; Reznikoff G; Dranoff G; Breakefield X O; Yu J S
Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.
Cancer gene therapy 1997;4(6):345-52.
1997: Ozelius L J; Hewett J W; Page C E; Bressman S B; Kramer P L; Shalish C; de Leon D; Brin M F; Raymond D; Corey D P; Fahn S; Risch N J; Buckler A J; Gusella J F; Breakefield X O
The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein.
Nature genetics 1997;17(1):40-8.
1997: Kaye E M; Shalish C; Livermore J; Taylor H A; Stevenson R E; Breakefield X O
beta-Galactosidase gene mutations in patients with slowly progressive GM1 gangliosidosis.
Journal of child neurology 1997;12(4):242-7.
1997: Bressman S B; de Leon D; Raymond D; Greene P E; Brin M F; Fahn S; Ozelius L J; Breakefield X O; Kramer P L; Risch N J
Secondary dystonia and the DYTI gene.
Neurology 1997;48(6):1571-7.
1997: Yu J S; Burwick J A; Dranoff G; Breakefield X O
Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells.
Human gene therapy 1997;8(9):1065-72.
1997: Ozelius L J; Hewett J; Kramer P; Bressman S B; Shalish C; de Leon D; Rutter M; Risch N; Brin M F; Markova E D; Limborska S A; Ivanova-Smolenskaya I A; McCormick M K; Fahn S; Buckler A J; Gusella J F; Breakefield X O
Fine localization of the torsion dystonia gene (DYT1) on human chromosome 9q34: YAC map and linkage disequilibrium.
Genome research 1997;7(5):483-94.
1997: Johnston K M; Jacoby D; Pechan P A; Fraefel C; Borghesani P; Schuback D; Dunn R J; Smith F I; Breakefield X O
HSV/AAV hybrid amplicon vectors extend transgene expression in human glioma cells.
Human gene therapy 1997;8(3):359-70.
1996: Yu J S; Sena-Esteves M; Paulus W; Breakefield X O; Reeves S A
Retroviral delivery and tetracycline-dependent expression of IL-1beta-converting enzyme (ICE) in a rat glioma model provides controlled induction of apoptotic death in tumor cells.
Cancer research 1996;56(23):5423-7.
1996: Pechan P A; Fotaki M; Thompson R L; Dunn R; Chase M; Chiocca E A; Breakefield X O
A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors.
Human gene therapy 1996;7(16):2003-13.
1996: Kramm C M; Rainov N G; Sena-Esteves M; Barnett F H; Chase M; Herrlinger U; Pechan P A; Chiocca E A; Breakefield X O
Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment.
Human gene therapy 1996;7(16):1989-94.
1996: Rainov N G; Kramm C M; Aboody-Guterman K; Chase M; Ueki K; Louis D N; Harsh G R; Chiocca A; Breakefield X O
Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm.
Cancer gene therapy 1996;3(2):99-106.
1996: Gasser T; Bove C M; Ozelius L J; Hallett M; Charness M E; Hochberg F H; Breakefield X O
Haplotype analysis at the DYT1 locus in Ashkenazi Jewish patients with occupational hand dystonia.
Movement disorders : official journal of the Movement Disorder Society 1996;11(2):163-6.
1996: Battinelli E M; Boyd Y; Craig I W; Breakefield X O; Chen Z Y
Characterization and mapping of the mouse NDP (Norrie disease) locus (Ndp).
Mammalian genome : official journal of the International Mammalian Genome Society 1996;7(2):93-7.
1996: Kramm C M; Rainov N G; Sena-Esteves M; Chase M; Pechan P A; Chiocca E A; Breakefield X O
Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors.
Human gene therapy 1996;7(3):291-300.
1996: Tivol E A; Shalish C; Schuback D E; Hsu Y P; Breakefield X O
Mutational analysis of the human MAOA gene.
American journal of medical genetics 1996;67(1):92-7.
1996: Paulus W; Baur I; Boyce F M; Breakefield X O; Reeves S A
Self-contained, tetracycline-regulated retroviral vector system for gene delivery to mammalian cells.
Journal of virology 1996;70(1):62-7.
1996: Gasser T; Wszolek Z; Supala A; Trofatter J; Ozelius L; Uitti R J; Pfeiffer R F; Gusella J; Calne D; Breakefield X O
Genetic linkage studies in autosomal dominantly inherited L-DOPA responsive parkinsonism. Evaluation of candidate genes.
Advances in neurology 1996;69():87-95.
1995: Rainov N G; Zimmer C; Chase M; Kramm C M; Chiocca E A; Weissleder R; Breakefield X O
Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms.
Human gene therapy 1995;6(12):1543-52.
1995: Davar G; Bebrin W R; Day R; Breakefield X O
Gene delivery to mouse sensory neurons with herpes simplex virus: a model for postherpetic neuralgia and its treatment?
Neurology 1995;45(12 Suppl 8):S69.
1995: Wei M X; Tamiya T; Rhee R J; Breakefield X O; Chiocca E A
Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(10):1171-7.
1995: Kramm C M; Sena-Esteves M; Barnett F H; Rainov N G; Schuback D E; Yu J S; Pechan P A; Paulus W; Chiocca E A; Breakefield X O
Gene therapy for brain tumors.
Brain pathology (Zurich, Switzerland) 1995;5(4):345-81.
1995: Tamiya T; Wei M X; Chase M; Ono Y; Lee F; Breakefield X O; Chiocca E A
Transgene inheritance and retroviral infection contribute to the efficiency of gene expression in solid tumors inoculated with retroviral vector producer cells.
Gene therapy 1995;2(8):531-8.
1995: Pechan P A; Yoshida T; Panahian N; Moskowitz M A; Breakefield X O
Genetically modified fibroblasts producing NGF protect hippocampal neurons after ischemia in the rat.
Neuroreport 1995;6(4):669-72.
1995: Slaugenhaupt S A; Blumenfeld A; Liebert C B; Mull J; Lucente D E; Monahan M; Breakefield X O; Maayan C; Parada L; Axelrod F B
The human gene for neurotrophic tyrosine kinase receptor type 2 (NTRK2) is located on chromosome 9 but is not the familial dysautonomia gene.
Genomics 1995;25(3):730-2.
1995: Blumenfeld A; Lucente D E; Trofatter J A; Lerner T; Slaugenhaupt S A; Liebert C B; Monahan M; Haines J L; Gusella J F; Breakefield X O; Parysek L M
Peripherin gene is linked to keratin 18 gene on human chromosome 12.
Somatic cell and molecular genetics 1995;21(1):83-8.
1995: Hsu Y P; Schuback D E; Tivol E A; Shalish C; Murphy D L; Breakefield X O
Analysis of MAOA mutations in humans.
Progress in brain research 1995;106():67-75.
1995: Chen Z Y; Denney R M; Breakefield X O
Norrie disease and MAO genes: nearest neighbors.
Human molecular genetics 1995;4 Spec No():1729-37.
1995: Schuback D E; Chen Z Y; Craig I W; Breakefield X O; Sims K B
Mutations in the Norrie disease gene.
Human mutation 1995;5(4):285-92.
1994: Bressman S B; de Leon D; Kramer P L; Ozelius L J; Brin M F; Greene P E; Fahn S; Breakefield X O; Risch N J
Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation.
Annals of neurology 1994;36(5):771-7.
1994: Boviatsis E J; Park J S; Sena-Esteves M; Kramm C M; Chase M; Efird J T; Wei M X; Breakefield X O; Chiocca E A
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene.
Cancer research 1994;54(22):5745-51.
1994: Gasser T; Wszolek Z K; Trofatter J; Ozelius L; Uitti R J; Lee C S; Gusella J; Pfeiffer R F; Calne D B; Breakefield X O
Genetic linkage studies in autosomal dominant parkinsonism: evaluation of seven candidate genes.
Annals of neurology 1994;36(3):387-96.
1994: Andersen J K; Frim D M; Isacson O; Beal M F; Breakefield X O
Elevation of neuronal MAO-B activity in a transgenic mouse model does not increase sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Brain research 1994;656(1):108-14.
1994: Boviatsis E J; Scharf J M; Chase M; Harrington K; Kowall N W; Breakefield X O; Chiocca E A
Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.
Gene therapy 1994;1(5):323-31.
1994: Wei M X; Tamiya T; Chase M; Boviatsis E J; Chang T K; Kowall N W; Hochberg F H; Waxman D J; Breakefield X O; Chiocca E A
Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene.
Human gene therapy 1994;5(8):969-78.
1994: Boviatsis E J; Chase M; Wei M X; Tamiya T; Hurford R K; Kowall N W; Tepper R I; Breakefield X O; Chiocca E A
Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors.
Human gene therapy 1994;5(2):183-91.
1994: Lerner T J; Boustany R M; MacCormack K; Gleitsman J; Schlumpf K; Breakefield X O; Gusella J F; Haines J L
Linkage disequilibrium between the juvenile neuronal ceroid lipofuscinosis gene and marker loci on chromosome 16p 12.1.
American journal of human genetics 1994;54(1):88-94.
1994: Davar G; Kramer M F; Garber D; Roca A L; Andersen J K; Bebrin W; Coen D M; Kosz-Vnenchak M; Knipe D M; Breakefield X O
Comparative efficacy of expression of genes delivered to mouse sensory neurons with herpes virus vectors.
The Journal of comparative neurology 1994;339(1):3-11.
1994: Davar G; Kramer M F; Garber D; Roca A L; Andersen J K; Bebrin W; Coen D M; Kosz-Vnenchak M; Knipe D M; Breakefield X O
Gene transfer to sensory neurons using herpes virus vectors.
Gene therapy 1994;1 Suppl 1():S24.
1993: Chen Z Y; Battinelli E M; Woodruff G; Young I; Breakefield X O; Craig I W
Characterization of a mutation within the NDP gene in a family with a manifesting female carrier.
Human molecular genetics 1993;2(10):1727-9.
1993: Chen Z Y; Battinelli E M; Fielder A; Bundey S; Sims K; Breakefield X O; Craig I W
A mutation in the Norrie disease gene (NDP) associated with X-linked familial exudative vitreoretinopathy.
Nature genetics 1993;5(2):180-3.
1993: Andersen J K; Frim D M; Isacson O; Breakefield X O
Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter.
Cellular and molecular neurobiology 1993;13(5):503-15.
1993: Takamiya Y; Short M P; Moolten F L; Fleet C; Mineta T; Breakefield X O; Martuza R L
An experimental model of retrovirus gene therapy for malignant brain tumors.
Journal of neurosurgery 1993;79(1):104-10.
1993: Blumenfeld A; Slaugenhaupt S A; Axelrod F B; Lucente D E; Maayan C; Liebert C B; Ozelius L J; Trofatter J A; Haines J L; Breakefield X O
Localization of the gene for familial dysautonomia on chromosome 9 and definition of DNA markers for genetic diagnosis.
Nature genetics 1993;4(2):160-4.
1993: Chen Z Y; Battinelli E M; Hendriks R W; Powell J F; Middleton-Price H; Sims K B; Breakefield X O; Craig I W
Norrie disease gene: characterization of deletions and possible function.
Genomics 1993;16(2):533-5.
1993: Yan W; Boustany R M; Konradi C; Ozelius L; Lerner T; Trofatter J A; Julier C; Breakefield X O; Gusella J F; Haines J L
Localization of juvenile, but not late-infantile, neuronal ceroid lipofuscinosis on chromosome 16.
American journal of human genetics 1993;52(1):89-95.
1993: Blumenfeld A; Axelrod F B; Trofatter J A; Maayan C; Lucente D E; Slaugenhaupt S A; Liebert C B; Ozelius L J; Haines J L; Breakefield X O
Exclusion of familial dysautonomia from more than 60% of the genome.
Journal of medical genetics 1993;30(1):47-52.
1992: Girmen A S; Baenziger J; Hotamisligil G S; Konradi C; Shalish C; Sullivan J L; Breakefield X O
Relationship between platelet monoamine oxidase B activity and alleles at the MAOB locus.
Journal of neurochemistry 1992;59(6):2063-6.
1992: Mikati M A; Maguire H; Barlow C F; Ozelius L; Breakefield X O; Klauck S M; Korf B; O'Tuama S L; Dangond F
A syndrome of autosomal dominant alternating hemiplegia: clinical presentation mimicking intractable epilepsy; chromosomal studies; and physiologic investigations.
Neurology 1992;42(12):2251-7.
1992: Ozelius L J; Kwiatkowski D J; Schuback D E; Breakefield X O; Wexler N S; Gusella J F; Haines J L
A genetic linkage map of human chromosome 9q.
Genomics 1992;14(3):715-20.
1992: Takamiya Y; Short M P; Ezzeddine Z D; Moolten F L; Breakefield X O; Martuza R L
Gene therapy of malignant brain tumors: a rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retrovirus kills other tumor cells.
Journal of neuroscience research 1992;33(3):493-503.
1992: Titlow C C; Andersen J K; Trofatter J A; Breakefield X O
In vitro translation of proteins with terminal deletions by SP6 RNA polymerase-mediated transcription of PCR products.
PCR methods and applications 1992;2(2):172-4.
1992: Gasser T; Fahn S; Breakefield X O
The autosomal dominant dystonias.
Brain pathology (Zurich, Switzerland) 1992;2(4):297-308.
1992: Andersen J K; Garber D A; Meaney C A; Breakefield X O
Gene transfer into mammalian central nervous system using herpes virus vectors: extended expression of bacterial lacZ in neurons using the neuron-specific enolase promoter.
Human gene therapy 1992;3(5):487-99.
1992: Chen Z Y; Hendriks R W; Jobling M A; Powell J F; Breakefield X O; Sims K B; Craig I W
Isolation and characterization of a candidate gene for Norrie disease.
Nature genetics 1992;1(3):204-8.
1992: Andersen J K; Herrup K; Breakefield X O
Creation of transgenic mice that overexpress monoamine oxidase-B neuronally.
Annals of the New York Academy of Sciences 1992;648():241-3.
1992: Sims K B; Lebo R V; Benson G; Shalish C; Schuback D; Chen Z Y; Bruns G; Craig I W; Golbus M S; Breakefield X O
The Norrie disease gene maps to a 150 kb region on chromosome Xp11.3.
Human molecular genetics 1992;1(2):83-9.
1992: Ozelius L; Schuback D E; Stefansson K; Slaugenhaupt S; Gusella J F; Breakefield X O
Dinucleotide repeat polymorphism for the hexabrachion gene (HXB) on chromosome 9q32-34.
Human molecular genetics 1992;1(2):141.
1992: Huang Q; Vonsattel J P; Schaffer P A; Martuza R L; Breakefield X O; DiFiglia M
Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study.
Experimental neurology 1992;115(3):303-16.
1992: Haines J L; Yan W L; Boustany R M; Jewell A; Julier C; Breakefield X O; Gusella J F
Linkage analysis in juvenile neuronal ceroid lipofuscinosis.
American journal of medical genetics 1992;42(4):542-5.
1992: Konradi C; Ozelius L; Breakefield X O
Highly polymorphic (GT)n repeat sequence in intron II of the human MAOB gene.
Genomics 1992;12(1):176-7.
1991: Konradi C; Ozelius L; Yan W; Gusella J F; Breakefield X O
Dinucleotide repeat polymorphism (D16S285) on human chromosome 16.
Nucleic acids research 1991;19(19):5449.
1991: Schuback D E; Ozelius L; Breakefield X O
BanI RFLP at AK1 locus (9q34).
Nucleic acids research 1991;19(20):5798.
1991: Chen Z Y; Hotamisligil G S; Huang J K; Wen L; Ezzeddine D; Aydin-Muderrisoglu N; Powell J F; Huang R H; Breakefield X O; Craig I
Structure of the human gene for monoamine oxidase type A.
Nucleic acids research 1991;19(16):4537-41.
1991: Kwiatkowski D J; Ozelius L; Kramer P L; Perman S; Schuback D E; Gusella J F; Fahn S; Breakefield X O
Torsion dystonia genes in two populations confined to a small region on chromosome 9q32-34.
American journal of human genetics 1991;49(2):366-71.
1991: Hotamisligil G S; Breakefield X O
Human monoamine oxidase A gene determines levels of enzyme activity.
American journal of human genetics 1991;49(2):383-92.
1991: Ezzeddine Z D; Martuza R L; Platika D; Short M P; Malick A; Choi B; Breakefield X O
Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene.
The New biologist 1991;3(6):608-14.
1991: Breakefield X O; DeLuca N A
Herpes simplex virus for gene delivery to neurons.
The New biologist 1991;3(3):203-18.
1991: Kwiatkowski D J; Nygaard T G; Schuback D E; Perman S; Trugman J M; Bressman S B; Burke R E; Brin M F; Ozelius L; Breakefield X O
Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindred.
American journal of human genetics 1991;48(1):121-8.
1991: Murphy D L; Sims K B; Karoum F; Garrick N A; de la Chapelle A; Sankila E M; Norio R; Breakefield X O
Plasma amine oxidase activities in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase.
Journal of neural transmission. General section 1991;83(1-2):1-12.
1990: Short M P; Choi B C; Lee J K; Malick A; Breakefield X O; Martuza R L
Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line.
Journal of neuroscience research 1990;27(3):427-39.
1990: Chiocca E A; Choi B B; Cai W Z; DeLuca N A; Schaffer P A; DiFiglia M; Breakefield X O; Martuza R L
Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants.
The New biologist 1990;2(8):739-46.
1990: Murphy D L; Sims K B; Karoum F; de la Chapelle A; Norio R; Sankila E M; Breakefield X O
Marked amine and amine metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase.
Journal of neurochemistry 1990;54(1):242-7.
1990: Schuback D E; Ozelius L; Hu G; Craft C M; Raese J; Breakefield X O; Hsu Y P
RFLP for human DBH (dopamine beta-hydroxylase).
Nucleic acids research 1990;18(2):387.
1990: Weyler W; Hsu Y P; Breakefield X O
Biochemistry and genetics of monoamine oxidase.
Pharmacology & therapeutics 1990;47(3):391-417.
1989: Hsu Y P; Powell J F; Sims K B; Breakefield X O
Molecular genetics of the monoamine oxidases.
Journal of neurochemistry 1989;53(1):12-8.
1989: Kwiatkowski D J; Ozelius L; Schuback D; Gusella J; Breakefield X O
The gelsolin (GSN) cDNA clone, from 9q32-34, identifies BclI and StuI RFLPs.
Nucleic acids research 1989;17(11):4425.
1989: Powell J F; Hsu Y P; Weyler W; Chen S A; Salach J; Andrikopoulos K; Mallet J; Breakefield X O
The primary structure of bovine monoamine oxidase type A. Comparison with peptide sequences of bovine monoamine oxidase type B and other flavoenzymes.
The Biochemical journal 1989;259(2):407-13.
1988: Hsu Y P; Weyler W; Chen S; Sims K B; Rinehart W B; Utterback M C; Powell J F; Breakefield X O
Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences.
Journal of neurochemistry 1988;51(4):1321-4.
1988: Geller A I; Breakefield X O
A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons.
Science (New York, N.Y.) 1988;241(4873):1667-9.
1983: Pintar J E; Levitt P; Salach J I; Weyler W; Rosenberg M B; Breakefield X O
Specificity of antisera prepared against pure bovine MAO-B.
Brain research 1983;276(1):127-39.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Xandra Breakefield

Research Profile (preview)

Chemicals & Drugs

Procedures

Living Beings

Disorders

Devices

Concepts & Ideas

Anatomy

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Xandra Breakefield (preview)

All Publications